Latest Healthcare News

Artrya Limited has responded to an ASX price query following a notable surge in its share price, confirming no undisclosed information and adherence to continuous disclosure rules.

Visioneering Technologies reports promising interim results from its PROTECT trial, showing significant control of myopia progression in children using NaturalVue® Multifocal lenses.

Pro Medicus has secured a $33 million, nine-year contract to implement its Visage 7 cloud-based imaging platform across the University of Kentucky’s health system, marking a significant expansion in North American academic healthcare.

Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Amcor plc and Berry Global Group, Inc. have entered into a definitive merger agreement for an all-stock transaction valued at approximately $9.9 billion. The combined entity aims to leverage significant synergies and enhanced market reach, pending shareholder and regulatory approvals.

Unith Ltd has strengthened its financial position through a partial divestment in AudioStack while renewing a key public health contract and achieving its highest B2C subscription revenue in two years.

4DMedical has landed a paid pilot contract with the US Department of Defense to deploy its CT:VQ™ lung imaging technology on active-duty personnel, marking a significant step before FDA submission and spotlighting a billion-dollar market opportunity.

Pacific Edge faces a significant Medicare reimbursement setback as Novitas finalizes a non-coverage decision for its Cxbladder tests, prompting the company to activate legal challenges and operational restructuring.

Titomic Limited has appointed Jim Simpson as Managing Director, consolidating leadership as the company accelerates its expansion in the US additive manufacturing market.

EBR Systems has announced a rescheduling of the FDA Pre-Approval Inspection for its wireless cardiac pacing device to January 14, 2025, while maintaining its regulatory approval timeline for Q1 2025 and a commercial launch later in the year.